A Paradigm Shift to Prevent and Treat Alzheimer's Disease
From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols
- 1st Edition - July 18, 2017
- Imprint: Academic Press
- Authors: Howard Friel, Sally A. Frautschy
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 2 2 5 9 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 2 2 7 9 - 2
A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols is the first book to systematically exhibit the power… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteA Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols is the first book to systematically exhibit the powerful pleiotropic pharmacological effects on Alzheimer’s disease of plant-based compounds from ancient foods that humans have been consuming safely with substantial health benefits for thousands of years.
These plant-based compounds include curcuminoids from turmeric, resveratrol from red wine and grape seed extract from other grape products, epigallocatechin-gallate (EGCG) from green tea, and oleocanthal and oleuropein from olive oil, in addition to a special extract, EGb 761, from the leaves of Ginkgo biloba, the oldest living species of tree on earth.
This book also presents a new analytical framework that convincingly favors a multi-targeting ("pleiotropic") approach to the prevention and treatment of complex chronic diseases, in contrast to the mono-targeting of the pharmaceutical model.
A Paradigm Shift to Prevent and Treat Alzheimer’s Disease
is a unique and exciting resource for pharmaceutical scientists, pharmacologists, neurologists, general practitioners, research scientists in various medical and life sciences, healthcare professionals in clinical and executive positions, conventional medical schools, schools of naturopathic medicine, healthcare and medical journalists, executives in both national public healthcare systems and private insurers, and informed general readers.- Presents carefully compiled evidence supporting the need to shift from pharmaceutical-based mono-targeting to plant polyphenol-based pleiotropic targeting for the prevention and treatment of Alzheimer’s disease
- Includes valuable tables that aggregate pleiotropic pharmacological effects of the plant polyphenols on Alzheimer’s disease-related pathogenic hallmarks
- Highlights regulatory aspects and discusses the challenges and potential solutions with respect to bioavailability of certain plant polyphenols
Researchers in Pharmacology and Pharmaceutical Science, Neurology and Neuroscience; Practicing Neurologists; Clinical Researchers; Family Practice Physicians, Medical Students; Medical and Healthcare Journalists
Part I1. Mono-targeting vs. Multi-targeting2. The Pleiotropic Pharmacology of Plant Polyphenols
Part II3. Primary Prevention of of Alzheimer's Disease4. Secondary Prevention of Alzheimer's Disease5. Treatment Mechanisms in Mild to Moderate Alzheimer's Disease6. Pleiotopic Theory
Part III7. Dose Adherence and Intent-to-Treat
- Edition: 1
- Published: July 18, 2017
- No. of pages (Paperback): 290
- No. of pages (eBook): 290
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128122594
- eBook ISBN: 9780128122792
HF
Howard Friel
Howard Friel is a book author who writes about foreign policy, public international law, international humanitarian law, human rights, civil liberties, and science-related issues. Friel has written four books to date: Chomsky and Dershowitz: On Endless War and the End of Civil Liberties (Olive Branch Press, 2014); The Lomborg Deception: Setting the Record Straight about Global Warming (Yale University Press, 2010); Israel-Palestine on Record: How the New York Times Misreports Conflict in the Middle East (with Richard Falk) (Verso, 2007), and The Record of the Paper: How the New York Times Misreports U.S. Foreign Policy (with Richard Falk) (Verso, 2004).
Affiliations and expertise
Book author who writes about foreign policy, public international law, international humanitarian law, and science-related issues, USASF
Sally A. Frautschy
Sally Frautschy is Professor of Neurology at the David Geffen School of Medicine at the University of California at Los Angeles. The laboratory that Frautschy founded with Greg Cole at UCLA conducts research to better understand the cellular, biochemical, and genetic pathways that disrupt cognition in Alzheimer's disease. Dr. Frautschy has coordinated her lab’s research with the NIH National Consortium Clinical Trials and the UCLA Alzheimer Center to accelerate effective prevention and treatment methods for Alzheimer’s disease.
Affiliations and expertise
Professor-in-Residence of Neurology, Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine, University of California, Los Angeles, VA Greater Los Angeles Healthcare System, West Los Angeles Medical CenterRead A Paradigm Shift to Prevent and Treat Alzheimer's Disease on ScienceDirect